Advancing healthcare provider TB testing with QuantiFERON-TB Gold Plus

Responsive image

Thank you

Thank you for your interest in QIAGEN microbiome workflow solutions.
A sales representative will contact you soon with your tailored discount offer.

REGISTER BELOW to view the on-demand webinar.

First Name*

Last Name*

Email address *

City*

State or Province*

Country*

Zip or Postal Code

Organization*

Job Profession*

What test do you most often use as part of your clinical assessment for diagnosis of LTBI?

Interferon-gamma release assay (IGRA): QuantiFERON®-TB Gold (Plus)

Interferon-gamma release assay (IGRA): T-SPOT®.TB

Tuberculin Skin Test (TST) / Mantoux

Not applicable

On average, how many TB tests does your practice perform a month?

I want to be the first to hear about offers and news from QIAGEN. *

I hereby give QIAGEN the consent to contact me via email and phone (subject to the contact information provided above) with further special offers, contests and product information.

BANT_Budget*

For SP creation / could be hidden field

BANT_Authority*

For SP creation / could be hidden field

BANT_Need*

For SP creation / could be hidden field

BANT_Time*

For SP creation / could be hidden field

Product Line Interest

Primary Campaign Source

For SP creation / could be hidden field

Specific Interest

Lead Source - Most Recent*

For SP creation / could be hidden field

Interaction Request*

For SP creation / could be hidden field

Opportunity Type*

For SP creation / could be hidden field

Buying Type

If Opp Type is INSTRUMENT // For SP creation / could be hidden field

Instrument Type

If Opp Type is INSTRUMENT // For SP creation / could be hidden field

Advancing healthcare provider TB testing with QuantiFERON-TB Gold Plus

Healthcare providers (HCPs) are at increased risk for TB infection and can benefit from systematic testing and treatment of latent TB infection. Over the past 15 years, laboratory-based TB interferon gamma release assays (IGRAs) have been transforming screening programs with higher accuracy, operational advantages and convenience to healthcare providers. Evolving policies and recent technological advances in both LTBI treatment and testing represent a new evolutionary step in tuberculosis infection control.

In this webinar, Dr. Masae Kawamura, QIAGEN’s Senior Director of Medical and Scientific Affairs, will provide an overview of the standard policies and practices of screening HCPs for TB infection. Dr. Kawamura will also discuss new preventive treatment regimens, the use of IGRAs as a primary screening method and the benefits of QIAGEN’s fourth-generation IGRA, QuantiFERON-TB Gold Plus (QFT-Plus) – which represents the latest evolution of IGRA technology and adds exclusive CD8 T cell technology.

QuantiFERON-TB Gold Plus (QFT-Plus) is an in vitro diagnostic aid for detection of Mycobacterium tuberculosis infection. QFT-Plus is an indirect test for M. tuberculosis infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations. QFT-Plus Package Inserts as well as up-to- date licensing information and product-specific disclaimers can be found at www.QuantiFERON.com.

* Subject to your consent given above, QIAGEN may use your personal information for internal business and marketing purposes. The information will not be sold to any third party. QIAGEN may transfer your personal information to our CRM system (hosted by SalesForce.com, Inc. and Oracle Corp.) solely for the purposes of data hosting and QIAGEN email distribution. You may unsubscribe at any time. Your data will be processed in compliance with applicable privacy laws, including the EU General Data Protection Regulation. For further details, please refer to our Privacy Policy.